---
annotation-target: 1-s2.0-S0006497122010758-main.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-16T13:36:40.610Z","updated":"2022-09-16T13:36:40.610Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":140,"end":158},{"type":"TextQuoteSelector","exact":"Non-canonical EZH2","prefix":"776-0545editorial@hematology.org","suffix":" drives retinoic acid resistance"}]}]}
>```
>%%
>*%%PREFIX%%776-0545editorial@hematology.org%%HIGHLIGHT%% ==Non-canonical EZH2== %%POSTFIX%%drives retinoic acid resistance*
>%%LINK%%[[#^g3myh7k25ff|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^g3myh7k25ff


>%%
>```annotation-json
>{"created":"2022-09-16T13:37:01.208Z","updated":"2022-09-16T13:37:01.208Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":4478,"end":4501},{"type":"TextQuoteSelector","exact":"Single-cell multi-omics","prefix":"e.duprez@inserm.fr    KEYWORDS  ","suffix":"; Leukemia resistance; Retinoic "}]}]}
>```
>%%
>*%%PREFIX%%e.duprez@inserm.fr    KEYWORDS%%HIGHLIGHT%% ==Single-cell multi-omics== %%POSTFIX%%; Leukemia resistance; Retinoic*
>%%LINK%%[[#^gf7b1tbv5nh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^gf7b1tbv5nh


>%%
>```annotation-json
>{"created":"2022-09-16T13:37:20.513Z","updated":"2022-09-16T13:37:20.513Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":4636,"end":4835},{"type":"TextQuoteSelector","exact":"Single cell multi-omics in PLZF-RARA leukemic cells resolves retinoic acid resistance network  •  Targeting pan-EZH2 activities (canonical/non-canonical) eradicates leukemia relapse-initiating cells ","prefix":"nonical EZH2 in leukemia     •  ","suffix":"     2  ABSTRACT   Cancer cell h"}]}]}
>```
>%%
>*%%PREFIX%%nonical EZH2 in leukemia     •%%HIGHLIGHT%% ==Single cell multi-omics in PLZF-RARA leukemic cells resolves retinoic acid resistance network  •  Targeting pan-EZH2 activities (canonical/non-canonical) eradicates leukemia relapse-initiating cells== %%POSTFIX%%2  ABSTRACT   Cancer cell h*
>%%LINK%%[[#^3mc7ceew7fd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^3mc7ceew7fd


>%%
>```annotation-json
>{"created":"2022-09-16T13:38:07.448Z","updated":"2022-09-16T13:38:07.448Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":5191,"end":5778},{"type":"TextQuoteSelector","exact":" We identified a subset of cells resistant to RA with proliferation, DNA replication and repair signatures, that depend on a fine-tuned E2F transcriptional network targeting the epigenetic regulator Enhancer of Zeste Homolog 2 (EZH2). Epigenomic and functional analyses validated the driver role of EZH2 in RA resistance. Targeting pan-EZH2  activities  (canonical/non-canonical)  was  necessary  to  eliminate  leukemia  relapse initiating cells, which underlies a dependency of resistant cells on an EZH2 non-canonical activity and the necessity to degrade EZH2 to overcome resistance.","prefix":"heterogeneity in leukemia cells.","suffix":" Our study provides critical ins"}]}]}
>```
>%%
>*%%PREFIX%%heterogeneity in leukemia cells.%%HIGHLIGHT%% ==We identified a subset of cells resistant to RA with proliferation, DNA replication and repair signatures, that depend on a fine-tuned E2F transcriptional network targeting the epigenetic regulator Enhancer of Zeste Homolog 2 (EZH2). Epigenomic and functional analyses validated the driver role of EZH2 in RA resistance. Targeting pan-EZH2  activities  (canonical/non-canonical)  was  necessary  to  eliminate  leukemia  relapse initiating cells, which underlies a dependency of resistant cells on an EZH2 non-canonical activity and the necessity to degrade EZH2 to overcome resistance.== %%POSTFIX%%Our study provides critical ins*
>%%LINK%%[[#^t5cpzvc7s2|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^t5cpzvc7s2


>%%
>```annotation-json
>{"created":"2022-09-16T13:40:56.186Z","updated":"2022-09-16T13:40:56.186Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":6175,"end":7257},{"type":"TextQuoteSelector","exact":"Acute promyelocytic leukemia (APL) is a class of acute myeloid leukemia (AML) that accounts for 10–15% of all cases and is characterized by recurrent chromosomal translocations involving invariably the gene encoding the Retinoic Acid Receptor alpha (RARA) (17q21) with several fusion partners, such as PML (15q22) or PLZF (11q23) (For review  1). The resulting X-RARA fusion proteins were among the first transcription factors (TFs) to be identified as drivers of cancer 2. They behave as RARA signaling repressors due to their ability to oligomerize and to recruit epigenetic repressors at cis-regulatory DNA regions of RARA target genes and initiate oncogenic gene expression signatures 3. APL patients with PML-RARA fusion, are exquisitely sensitive to Retinoic Acid (RA) treatment, a sensitivity that has made APL one of the most successful examples of targeted therapy to mutational events 4; 5. However, APL variant cases, such as the t(11;17), which represent 1% of APL cases still poses clinical challenges 6, as they respond poorly to RA and remain clinically resistant 7. ","prefix":"tant cells.        INTRODUCTION ","suffix":" 3  Contrary  to  PML-RARA  APL,"}]}]}
>```
>%%
>*%%PREFIX%%tant cells.        INTRODUCTION%%HIGHLIGHT%% ==Acute promyelocytic leukemia (APL) is a class of acute myeloid leukemia (AML) that accounts for 10–15% of all cases and is characterized by recurrent chromosomal translocations involving invariably the gene encoding the Retinoic Acid Receptor alpha (RARA) (17q21) with several fusion partners, such as PML (15q22) or PLZF (11q23) (For review  1). The resulting X-RARA fusion proteins were among the first transcription factors (TFs) to be identified as drivers of cancer 2. They behave as RARA signaling repressors due to their ability to oligomerize and to recruit epigenetic repressors at cis-regulatory DNA regions of RARA target genes and initiate oncogenic gene expression signatures 3. APL patients with PML-RARA fusion, are exquisitely sensitive to Retinoic Acid (RA) treatment, a sensitivity that has made APL one of the most successful examples of targeted therapy to mutational events 4; 5. However, APL variant cases, such as the t(11;17), which represent 1% of APL cases still poses clinical challenges 6, as they respond poorly to RA and remain clinically resistant 7.== %%POSTFIX%%3  Contrary  to  PML-RARA  APL,*
>%%LINK%%[[#^nbztj8o7uab|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^nbztj8o7uab


>%%
>```annotation-json
>{"created":"2022-09-16T13:42:08.275Z","updated":"2022-09-16T13:42:08.275Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":7553,"end":8061},{"type":"TextQuoteSelector","exact":"The PLZF moiety of the fusion is thought to play a determinant role in RA-resistance. PLZF is a potent transcriptional repressor that can interact by itself with epigenetic complexes 3; 10. Given that PLZF binding sites with corepressors are conserved in the PLZF-RARA fusion, one hypothesis is that inappropriate recruitment of functional epigenetic repressors, such as the Polycomb Repressor Complex 1 (PRC1), would trigger epigenetic imbalance at very specific genomic loci in an RA insensitive manner  11","prefix":"ntiation and tumor eradication. ","suffix":". This is consistent with the ob"}]}]}
>```
>%%
>*%%PREFIX%%ntiation and tumor eradication.%%HIGHLIGHT%% ==The PLZF moiety of the fusion is thought to play a determinant role in RA-resistance. PLZF is a potent transcriptional repressor that can interact by itself with epigenetic complexes 3; 10. Given that PLZF binding sites with corepressors are conserved in the PLZF-RARA fusion, one hypothesis is that inappropriate recruitment of functional epigenetic repressors, such as the Polycomb Repressor Complex 1 (PRC1), would trigger epigenetic imbalance at very specific genomic loci in an RA insensitive manner  11== %%POSTFIX%%. This is consistent with the ob*
>%%LINK%%[[#^jxoy944opa|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jxoy944opa


>%%
>```annotation-json
>{"created":"2022-09-16T13:43:15.769Z","updated":"2022-09-16T13:43:15.769Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":8558,"end":9334},{"type":"TextQuoteSelector","exact":"we  studied  PLZF-RARA  APL  cellular  heterogeneity  by  in tegrating  scRNA-seq  and scATAC-seq data obtained from an RA-treated PLZF-RARA mouse model. Establishing cellular clusters and arranging them in hierarchies helped us to identify a subpopulation of transformed promyelocytes that were insensitive to RA-induced differentiation and characterized by a high expression of Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2 (PRC2). Because EZH2 is an interesting cancer target 13, we further explored EZH2 function in APL development and RA treatment response. We discovered a dual role of EZH2 in APL onset and RA response, suggesting the need to target the non-histone methyltransferase activity of EZH2 for leukemia clearance.","prefix":"acilitate  treatment response,  ","suffix":"   METHODS A complete descriptio"}]}]}
>```
>%%
>*%%PREFIX%%acilitate  treatment response,%%HIGHLIGHT%% ==we  studied  PLZF-RARA  APL  cellular  heterogeneity  by  in tegrating  scRNA-seq  and scATAC-seq data obtained from an RA-treated PLZF-RARA mouse model. Establishing cellular clusters and arranging them in hierarchies helped us to identify a subpopulation of transformed promyelocytes that were insensitive to RA-induced differentiation and characterized by a high expression of Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2 (PRC2). Because EZH2 is an interesting cancer target 13, we further explored EZH2 function in APL development and RA treatment response. We discovered a dual role of EZH2 in APL onset and RA response, suggesting the need to target the non-histone methyltransferase activity of EZH2 for leukemia clearance.== %%POSTFIX%%METHODS A complete descriptio*
>%%LINK%%[[#^0mfh0r1kd4y|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0mfh0r1kd4y


>%%
>```annotation-json
>{"created":"2022-09-16T13:44:03.710Z","updated":"2022-09-16T13:44:03.710Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":10313,"end":10379},{"type":"TextQuoteSelector","exact":"Single-cell analyses were performed on the 10X Genomics platform. ","prefix":"(authorization number: 23893).  ","suffix":" For  single-cell  RNA-sequencin"}]}]}
>```
>%%
>*%%PREFIX%%(authorization number: 23893).%%HIGHLIGHT%% ==Single-cell analyses were performed on the 10X Genomics platform.== %%POSTFIX%%For  single-cell  RNA-sequencin*
>%%LINK%%[[#^x5sc9pdqu3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^x5sc9pdqu3


>%%
>```annotation-json
>{"created":"2022-09-16T13:44:26.924Z","updated":"2022-09-16T13:44:26.924Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":11056,"end":11166},{"type":"TextQuoteSelector","exact":"Data were processed using the 10X software Cell Ranger (v4.0) and the 10X software Cell Ranger ATAC (v1.2.0). ","prefix":"red-end protocol, respectively. ","suffix":"The mm10 genome was used as refe"}]}]}
>```
>%%
>*%%PREFIX%%red-end protocol, respectively.%%HIGHLIGHT%% ==Data were processed using the 10X software Cell Ranger (v4.0) and the 10X software Cell Ranger ATAC (v1.2.0).== %%POSTFIX%%The mm10 genome was used as refe*
>%%LINK%%[[#^zw8txam9oae|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zw8txam9oae


>%%
>```annotation-json
>{"created":"2022-09-16T13:45:32.362Z","updated":"2022-09-16T13:45:32.362Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":15410,"end":15567},{"type":"TextQuoteSelector","exact":"Altogether, these results reveal transcriptional heterogeneity and differentiation states within the PLZF-RARA transformed cells and identify the ReP cluster","prefix":"transplanted mice (Figure 1L).  ","suffix":", which exhibits no differentiat"}]}]}
>```
>%%
>*%%PREFIX%%transplanted mice (Figure 1L).%%HIGHLIGHT%% ==Altogether, these results reveal transcriptional heterogeneity and differentiation states within the PLZF-RARA transformed cells and identify the ReP cluster== %%POSTFIX%%, which exhibits no differentiat*
>%%LINK%%[[#^lybyk2tta5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lybyk2tta5


>%%
>```annotation-json
>{"created":"2022-09-16T13:45:47.456Z","updated":"2022-09-16T13:45:47.456Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":15616,"end":15733},{"type":"TextQuoteSelector","exact":"high E2F signature and PLZF-RARA residual expression as the potential driver of RA resistance of PLZF-RARA leukemia. ","prefix":"no differentiation 6  features, ","suffix":" Single-cell integrative multi-o"}]}]}
>```
>%%
>*%%PREFIX%%no differentiation 6  features,%%HIGHLIGHT%% ==high E2F signature and PLZF-RARA residual expression as the potential driver of RA resistance of PLZF-RARA leukemia.== %%POSTFIX%%Single-cell integrative multi-o*
>%%LINK%%[[#^aana7ul8xtg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^aana7ul8xtg


>%%
>```annotation-json
>{"created":"2022-09-16T13:47:12.171Z","updated":"2022-09-16T13:47:12.171Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":18131,"end":18290},{"type":"TextQuoteSelector","exact":"The results show that RA resistance depends on E2F transcriptional activity and relies on differences in chromatin accessibility, mainly at enhancer regions.  ","prefix":"ir, replication and chromatin.  ","suffix":"EZH2 is necessary for PLZF-RARA "}]}]}
>```
>%%
>*%%PREFIX%%ir, replication and chromatin.%%HIGHLIGHT%% ==The results show that RA resistance depends on E2F transcriptional activity and relies on differences in chromatin accessibility, mainly at enhancer regions.== %%POSTFIX%%EZH2 is necessary for PLZF-RARA*
>%%LINK%%[[#^jhg77ciy8zj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jhg77ciy8zj


>%%
>```annotation-json
>{"created":"2022-09-16T13:50:49.180Z","updated":"2022-09-16T13:50:49.180Z","document":{"title":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","link":[{"href":"urn:x-pdf:03902474b54baeb62bd146caa3201816"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf"}],"documentFingerprint":"03902474b54baeb62bd146caa3201816"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010758-main.pdf","selector":[{"type":"TextPositionSelector","start":30836,"end":31059},{"type":"TextQuoteSelector","exact":"Clonal diversity and evolution patterns of AML by high-throughput single-cell genomics (scRNA-seq and scDNA-seq) have revealed hierarchies in the AML with heterogeneity correlating with their underlying genetic alterations2","prefix":"echanisms could widen its use.  ","suffix":"6; 27. Here, we analyzed the eff"}]}]}
>```
>%%
>*%%PREFIX%%echanisms could widen its use.%%HIGHLIGHT%% ==Clonal diversity and evolution patterns of AML by high-throughput single-cell genomics (scRNA-seq and scDNA-seq) have revealed hierarchies in the AML with heterogeneity correlating with their underlying genetic alterations2== %%POSTFIX%%6; 27. Here, we analyzed the eff*
>%%LINK%%[[#^jn3ynqbaxgb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jn3ynqbaxgb
